Both in vitro and in vivo dsRNAs for CMV CP (657 bps) and 2b (336 bps), resistant to DNase and RNase A treatments, were produced in sufficient quantities [3–4 μg/μL in vitro dsRNA-CP (dsCP) or in vitro dsRNA-2b (ds2b) or in vivo ds2b; 0.1–0.3 μg/μL in vivo dsCP; as estimated on agarose gel after RNase A/DNase I treatment, Supplementary Figure S2], and then tested for their protective effects against CMV infection in Nicotiana tabacum and C. quinoa plants. This evidence concerns the gene RNASE1 and cytomegalovirus infection.